K
Klotho Neurosciences, Inc. (KLTO)
NCM – Real Time Price. Currency in USD
0.52
+0.00 (0.81%)
At close: Mar 11, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.52
+0.00 (0.81%)
At close: Mar 11, 2026, 4:00 PM EDT
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
| Name | Position |
|---|---|
| Dr. Joseph A. Sinkule Pharm.D. | Founder, CEO, Chairman of the Board & Secretary |
| Dr. Miguel Chillon Rodriguez | Chief Scientific Officer & Consultant |
| Dr. Shalom Z. Hirschman M.D. | Medical Advisor & Director |
| Mr. Jeffrey LeBlanc | Chief Financial Officer |
| Mr. Peter J. Moriarty | Chief Business Officer |
| Date | Type | Document |
|---|---|---|
| 2026-01-26 | DEFR14A | ea0272598-03.htm |
| 2026-01-23 | DEF 14A | ea0272598-02.htm |
| 2026-01-12 | PRE 14A | ea0272598-01.htm |
| 2025-12-08 | 8-K | ea0268846-8k_klotho.htm |
| 2025-12-05 | S-1 | ea0268254-s1_klotho.htm |
| 2025-11-13 | 10-Q | ea0264459-10q_klotho.htm |
| 2025-11-06 | S-8 | ea0261864-s8_klotho.htm |
| 2025-09-25 | 8-K | ea0258847-8k_klotho.htm |
| 2025-08-18 | 10-Q | ea0253157-10q_klotho.htm |
| 2025-08-14 | NT 10-Q | ea0253155-nt10q_klotho.htm |